ArticleScientific reports2025
Prevalence and impact of thyroid dysfunction in patients with rheumatoid arthritis.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Thyroid hormone changes after tumor necrosis factor inhibitor therapy in euthyroid patients with rheumatic diseases.BMC pharmacology & toxicology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Thyroid disorders are common in patients with autoimmune diseases such as rheumatoid arthritis (RA). Both conditions present significant public health concerns due to their impact on quality of life and increased mortality. The aim of this study was to assess the prevalence of thyroid abnormalities in and investigate their influence on rheumatoid arthritis characteristics. This was a case-control study involving adult female patients with RA and age-matched healthy controls. RA disease activity was evaluated using the Disease Activity Score (DAS28), and functional impact was assessed using the Health Assessment Questionnaire (HAQ). Serum thyroid function tests were performed, including thyroid-stimulating hormone (TSH), free thyroxine (FT4), and antithyroid antibodies (TAAs), including anti-thyroglobulin antibodies (TgAb), anti-thyroperoxidase antibodies (TPOAb), and TSH receptor antibodies (TRAb). The study included 58 female RA patients, with a mean age of 52 ± 14.2 years. The median disease duration was 10.41 years. The median DAS28-CRP was 4.03, and the median HAQ was 1.34. The median FT4 and TSH levels were 15.01 [13.48;16.71] and 1.42 [0.91;2.26], respectively. Thyroid dysfunction was identified in 19% of the participants, with hypothyroidism being the most common disorder (17%). Hyperthyroidism was observed in 2% of patients. Antithyroid antibodies were positive in 15.5% (n = 9) of participants, with TPOAb present in 6 patients (10.3%), TgAb in 3 patients (5.2%), and TRAb in 2 patients (3.4%). No statistically significant association was found between thyroid status and RA disease activity, functional impact, or serological status. Despite the lack of correlation, the high prevalence of thyroid dysfunction underscores the importance of regular thyroid screening to optimize management and prognosis in RA patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.